Unintended consequences of the Inflation Reduction Act: clinical development toward subsequent Indications

• Published in: The American journal of managed care 2024-02, Vol.30 (2), p.82-86
• Main Authors: Patterson, Julie, Motyka, James, O'Brien, John Michael
• Format: Article
• Language: English
• Subjects: Clinical trials; Drug prices; FDA approval; Inflation Reduction Act 2022-US; Medicare; Oncology; Patients; Prescription drugs; R&D; Research & development
• ISSN: 1088-0224; 1936-2692; 1936-2692
• DOI: 10.37765/ajmc.2024.89495

 To describe the clinical development landscape for high-spend Medicare Part D small molecule drugs and illustrate the potential impact of the Inflation Reduction Act of 2022 (IRA) on research and development investments toward subsequent indications. Descriptive analysis of research and development time lines of small molecule drugs in the top 50 of 2020 Medicare Part D spending using publicly available dates when pivotal clinical trials were first posted to ClinicalTrials.gov and FDA approval dates for initial and subsequent indications.  We summarize the drugs, indications, and time lines using descriptive statistics. Thirty of the 50 drugs with highest gross spending by Medicare Part D in 2020 were small molecule drugs with subsequent indications. Subsequent indications based on preapproval research (n = 34) were often approved within 2 years of initial approval (n = 15) and, on average, 2.9 years after a drug's first approval. Additional indications based on postapproval clinical trials or real-world evidence (n = 42) received FDA approval, on average, 7.5 years after a drug was first approved, with the majority (55.8%) receiving FDA approval more than 7 years after the initial approval. Our analysis of clinical development for new indications reveals aspects of innovation in small molecule drugs that are at risk under the IRA. Specifically, the time lines described in this research demonstrate how the IRA may reduce economic incentives to develop multiple indications, including single-indication launches and investments in postapproval research for additional indications.